The company said the placement is part of an agreement to sell up to 9.7 million restricted shares and warrants for another 5 million shares during the third quarter. * LeuKoSite Inc., of Cambridge, Mass., expanded its 1994 collaboration with Warner-Lambert Co., of Morris Plains, N.J., to develop small molecule inhibitors of chemokines, which are believed to be involved in inflammatory and autoimmune diseases

29, 1995 to determine whether fenfluramine and its isomers should be removed from the federal list of controlled substances. * PerSeptive Biosystems Inc., of Farmingham, Mass., said the U.S. District Court in Boston accepted settlement of a class action shareholder lawsuit against the company...The suit was filed in 1994 after PerSeptive was forced to recalculate a series of quarterly financial statements...The takeover was announced in July. (See BioWorld Today Special News Bulletin, July 10, 1995

A designation as a combination product, based on the product's glycerol content, would have required Osteotech to conduct clinical studies. * Protein Polymer Technologies Inc., of San Diego, said holders of its Series C preferred stock provided the company with a $500,000 bridge loan. (c) 1997 American Health Consultants

GeneMedicine Inc., of The Woodlands, Texas, and Medi-Ject Corp., of Minneapolis, are collaborating to develop needle-free injection devices to enhance the delivery of genes to certain tissues. * HemaSure Inc., of Marlborough, Mass., registered to sell 2.5 million shares of common stock. * Mycogen Corp., of San Diego, and Ciba-Geigy Ltd.'s Seed Division, of Greensboro, N.C., received Environmental Protection Agency approval to market seeds for corn hybrids that are genetically engineered to

The drug uses a CD4 protein to attract the virus and remove it from the bloodstream

The company's lead compound, Synovir, whose generic name is thalidomide, is for HIV, cachexia associated with AIDS, cancer and rheumatoid arthritis. * CellPro Inc., of Seattle, said a federal district court jury in Delaware has decided that the company's Ceprate SC Stem Cell Concentration System and its Ceprate LC Laboratory Cell Separation System do not infringe patents held by Johns Hopkins University, of Baltimore, and licensed to Becton Dickinson and Co., of Franklin Lakes, N.J., and Baxter

to certain technology for the use of paclitaxel in the treatment of rheumatoid arthritis and similar conditions. * MDS Health Group Ltd., of Toronto, purchased Panlabs International Inc., a Seattle-based contract research organization. * Oncogene Science Inc., of Uniondale, N.Y., completed the sale of its Research Products Business to Calbiochem- Novabiochem International Inc., of San Diego, for $6 million and other considerations. * Alteon Inc., of Ramsey, N.J., adopted a stockholder rights

OncorMed has exclusive worldwide rights to HCI's hereditary database and added exclusive worldwide commercialization rights to HCI's DNA library. * Paraxel International Corp., a Boston-based contract research organization, opened offices in Milan, Italy, and Kobe, Japan. * Therexsys Ltd., of Staffordshire, England, signed an agreement with Gryphon Sciences, of South San Francisco, to evaluate Gryphon's chemical ligation technologies in Therexsys' targeted gene-delivery system. * Allelix

It said the move is not in response to specific takeover attempts. * CellPro Inc., of Seattle, was granted the use of the CE marking designating full marketing approval throughout Europe for its Ceprate SC Stem Cell Concentration System...The deal, which is in the option stage, calls for the screening of Neurex's library of synthetic peptides and natural compounds isolated from invertebrate venom fractions for selective insecticidal activity. * Sugen Inc., of Redwood City, Calif., adopted a

The treatment is being made available free to people with Lou Gehrig's disease pending the FDA's review of the company's new drug application...Gilead will get $1.25 million to fund research during the extension. * Celgene Corp., of Warren, N.J., and Johns Hopkins University, of Baltimore, will conduct a pilot preclinical program to assess the potential of thalidomide-related drugs in graft-vs.-host disease. (c) 1997 American Health Consultants

* Ligand Pharmaceuticals Inc., of San Diego, launched the sale of Photofrin, a light-activated drug, in Canada for esophageal cancer and superficial bladder cancer. The company licensed the product from QLT PhotoTherapeutics Inc., of Vancouver, Canada. Photofrin is Ligand's second drug on the market in Canada. The first was Proleukin, which is made by Emeryville, Calif.- based Chiron Corp. (c) 1997 American Health Consultants. All rights reserved.

CPC-211 was designed to reduce accumulation of lactate, which causes brain damage in stroke victims...Texas Biotechnology expects to begin Phase I tests for pulmonary hypertension in early 1996. * The National Organization for Rare Disorders (NORD), of New Fairfield, Conn., said the first 1,250 amyotrophic lateral sclerosis patients were chosen to receive Rilutek, a drug made by Rhone-Poulenc Rorer Inc., of Collegeville, Pa

The Immune Response Corp., of Carlsbad, Calif., received FDA clearance to test its psoriasis therapy in a Phase II trial. * Protein Design Labs Inc., of Mountain View, Calif., began a Phase II trials of its monoclonal antibody for treatment of cytomegalovirus (CMV) retinitis in AIDS patients...In addition, Johns Hopkins University and the National Eye Institute will conduct a separate Phase II/III trial with the monoclonal antibody for CMV in AIDS patients. * Rhone-Poulenc Rorer Inc., of

EnzyMed Inc., of Iowa City, which uses enzyme- based combinatorial chemistry to create libraries of organic molecules, entered a research collaboration with DuPont Agricultural Products, a subsidiary of the Wilmington, Del.-based E.I. Du Pont & Co...Terms were not disclosed. * GenPharm International Inc., of Mountain View, Calif., sold its transgenic laboratory products division to Taconic Farms Inc., of Germantown, N.Y. Terms were not disclosed...Progenitor is a subsidiary of Interneuron

The company said defining the structure of the receptors may have implications for drugs to treat cancer, pain, schizophrenia as well as cardiac and metabolic disorders. * Applied Immune Sciences Inc...In addition, Receptor shareholders agreed to invest $1.5 million in Cytel to support continuation of the Charlottesville operation

Biochem Pharma Inc., of Laval, Quebec, said its joint venture filed a new drug submission in Canada for 3TC in combination with AZT for the treatment of HIV. * Genetic Therapy Inc., of Gaithersburg, Md., started a Phase I trial of a gene therapy protocol designed to protect patients' blood systems from the effects of high- dose chemotherapy...It said the action was not in response to any specific takeover proposal. * Targeted Genetics Corp., of Seattle, sold 52,000 additional units in a second

Symphony Pharmaceuticals Inc., of Malvern, Pa., was awarded a $1.7 million three-year grant from the National Institute of Standards and Technology, to research the modulation of protein expression as a way to identify compounds for treatment of a variety of disease. * QLT PhotoTherapeutics Inc., of Vancouver, Canada, received an approvable letter from the FDA for the company's light activated drug, Photofrin, as a palliative treatment for obstructing cancers of the esophagus...The drug uses CD4

It said the plan was not in response to a specific takeover threat or proposal. * Japan Tobacco Inc., of Tokyo, said it developed a technology to introduce genes into maize by using the microorganism Agrobacterium. * OxiGene Inc., of New York, adjusted the price of the warrants issued in connection with its initial public offering, reducing the price from $9 to $8.39. * Rhone-Poulenc Rorer Inc., of Collegeville, Pa., made a new drug submission in Canada seeking approval of Rilutek as a

It said the plan was not in response to a specific takeover threat or proposal. * Japan Tobacco Inc., of Tokyo, said it developed a technology to introduce genes into maize by using the microorganism Agrobacterium. * OxiGene Inc., of New York, adjusted the price of the warrants issued in connection with its initial public offering, reducing the price from $9 to $8.39. * Rhone-Poulenc Rorer Inc., of Collegeville, Pa., made a new drug submission in Canada seeking approval of Rilutek as a